Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The rationale is to assess the clinical and biological activity of Imatinib and to compare
the data with historic data.
Additionally this study has been designed to gain more experience with the treatment of GIST
in several Central and Eastern European Countries.